Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > fda max : 600 mg/d or Formulation-specific; ~4.8 g/d typical maximum oral & routes: Oral

Use the filters below to narrow your results.

generic:
Cefdinir (1) · Mesalamine (5-aminosalicylic acid, 5-ASA) (1)
brand:
Asacol HD, Pentasa, Lialda, Apriso, Delzicol, Rowasa (rectal), Canasa (suppository) (1) · Omnicef (discontinued in US under brand); mostly generic (1)
classes:
[[:Category:5-aminosalicylates|5-aminosalicylate (5-ASA)]] (1) · [[:Category:Anti-inflammatories|Anti-inflammatory]] (1) · [[:Category:Beta-lactam_antibiotics|β-lactam antibiotic]] (1) · [[:Category:Cephalosporins|Cephalosporin (third-generation)]] (1) · [[:Category:IBD_medications|IBD medication]] (1)
mechanism:
None (2)
uses:
'"`UNIQ--vote-000009DF-QINU`"', '"`UNIQ--vote-000009E0-QINU`"', '"`UNIQ--vote-000009E1-QINU`"', '"`UNIQ--vote-000009E2-QINU`"', '"`UNIQ--vote-000009E3-QINU`"' (1) · '"`UNIQ--vote-00000BBC-QINU`"', '"`UNIQ--vote-00000BBD-QINU`"' (1)
starting dose:
300 mg PO BID, or 600 mg PO once daily, ×5-10 days; pediatric 14 mg/kg/d (1) · Active UC: Lialda 2.4-4.8 g PO once daily, Apriso 1.5 g PO once daily; maintenance 1.2-2.4 g/d; rectal Rowasa enema 4 g HS for distal disease; Canasa 1 g suppository HS for proctitis (1)
preparations:
300 mg capsules; 125, 250 mg/5 mL suspension (1) · Multiple non-bioequivalent oral formulations (pH-, time-, and moisture-dependent release); rectal enema 4 g/60 mL; 1 g rectal suppository (1)
fda max: (Click arrow to add another value)
routes: (Click arrow to add another value)
onset:
Hours (1) · Symptomatic improvement 2-4 weeks (1)
duration:
12-24 hours (1) · 24 hours (most ER formulations) (1)
halflife:
~1.7 hours'"`UNIQ--ref-000009E4-QINU`"' (1) · ~5-10 hours (5-ASA)'"`UNIQ--ref-00000BBE-QINU`"' (1)
bioavailability:
16-21% capsule, 25% suspension (oral; iron and antacids reduce absorption substantially)'"`UNIQ--ref-000009E5-QINU`"' (1) · Highly formulation-dependent; the goal is colonic delivery with minimal systemic exposure'"`UNIQ--ref-00000BBF-QINU`"' (1)
pregnancy:
Generally considered safe at standard doses; benefits typically outweigh in active IBD.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Generally considered safe in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
[[USLegal:Prescription only|Rx-only]] in US (2)

Showing below up to 2 results in range #1 to #2.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"